We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Following the robust Q3 performance, Piper Sandler raised ABT’s price target to $133 from $131, keeping an Overweight rating ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Rather than applying a diagnostic label of Alzheimer's disease, we advocate for this being a state of risk." Feldman reported relationships with Annovis, Vivoryon, AC Immune, Biohaven, LuMind ...

He also reported relationships with Epitech, Roche, Novo Nordisk, and PIAM Farmaceutici ... trial of repetitive TMS of the ...

These diseases affect different parts of the brain, so they affect people in different ways. Most people with dementia have Alzheimer’s disease or vascular dementia but there are other types too. In ...

Two blood tests currently in development have shown 'very high accuracy' in detecting tell-tale signs of Alzheimer's disease, ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...